Nanosonics (ASX:NAN) — Material Events
ASX:NAN · 4 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Nanosonics Unleashes Faster trophon3 with FDA Nod, Targets 30,000 US DevicesMedium
Nanosonics gains FDA clearance for faster trophon3 device and trophon2 Plus upgrade, unlocking major US market growth
6 Aug 2025
·Product Launch / Regulatory Clearance
·85
Nanosonics Grows Revenue 9% as CORIS Prepares for Market DebutMedium
Nanosonics FY26 H1 revenue up 9%, strong installed base growth, CORIS commercialisation underway
24 Feb 2026
·Investor Presentation
·85
Nanosonics Accelerates Growth with Trophon3 Launch and CORIS FDA ClearanceHigh
Nanosonics FY25 revenue up 17%, profit before tax up 72%, launches next-gen trophon and advances CORIS commercialisation
26 Aug 2025
·Full Year Financial Results
·85
No articles in this tier for the last 12 months.
Market Mentions
1
- appeared in market wrap coverage
These are market wrap articles where Nanosonics (ASX:NAN) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026